Author/Editor		Modic, Mojca; Kralj, Jana; Čibej, Lara; Mlakar, Uroš
Title		Koncentracije nekaterih dejavnikov angiogeneze v serumu pri diseminiranem plazmocitomu: VEGF, bFGF in MMP-9
Translated title		Serum concentrations of some angiogeneic factors in multiple myeloma: VEGF, bFGF in MMP-9
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 73, št. Suppl 1
Publication year		2004
Volume		str. I-39-42
Language		slo
Abstract		Background. Angiogenesis is a crucial process in progression of multiple myeloma. Vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) are multifunctional cytokines that stimulate angiogenesis and myeloma growth. Matrix metalloproteinase 9 (MMP-9) plays a critical role in osteolytic bone destruction, angiogenesis and invasive growth of myeloma cells. We evaluated serum concentrations of these factors in patients with multiple myeloma. Methods. Levels of active and pro-matrix metalloproteinase 9 (total MMP-9), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) were determined with a commercial quantitative enzyme immunoassay Quantikine® (R and D Systems, USA). All of these factors were measured in the serum, obtained from pheripheral blood of 36 patients affected by multiple myeloma. This series included 12 patients with disease in plateau phase and without treatment, 24 patients on Thalidomide therapy and 10 patients at the beginning of chemotherapy because of active disease. Results. VEGF showed a strong correlation with MMP-9 while VEGF and bFGF did not correlate with each other. Blood platelets correlated with VEGF and MMP-9. The concentration of MMP-9 and VEGF were the highest in group of patients with active disease where the chemotherapy started. The level of bFGF was the lowest in the group devoid of treatment (plateau phase of disease). Conclusions. Production of the angiogenic factors such as VEGF, bFGF and MMP-9 are increased in multiple myeloma patients. The levels of these factors correlate with the activity of disease.
Summary		Izhodišča. Angiogeneza ima pomembno vlogo v patogenezi in napredovanju diseminiranega plazmocitoma (DP). Žilni endotelijski rastni dejavnik A (VEGF-A) in bazični fibroblastni rastni dejavnik (bFGF, FGF2) sta citokirta, ki spodbujata angiogenezo in delitev plazmocitonaskih celic. Matriks metaloproteaza-9 je encim, ki razgrajuje zunajcelični matriks. Njegovo delovanje je pomembno pri angiogenezi, širjenju celic novotvorbe v sosednje tkivo in za osteolitično razgradnjo kosti pri plazmocitomu. V naši raziskavi smo analizirali serumske koncentracije omenjenih dejavnikov pri DP. Preiskovanci in metode. Koncentracije VEGF-A, bFGF in MMP9 smo določili pri 36 bolnikih z DP. Dvanajst bolnikov z DP v obdobju, določanja dejavnikov angiogeneze ni potrebovalo zdravljenja, 14 bolnikov je prejemalo talidomid. Pri desetih bolnikih z razširjeno boleznijo smo določili angiogenetične dejavnike tik pred ali kmalu po začetku zdravljenja s citostatiki. Serumske koncentracijo MMP-9, VEGFA in bFGF smo določili na encimsko imunski način z reagenčnimi kompleti Quantikine® (R and D Systems, USA). Rezultati. Koncentraciji MMP-9 in VEGF sta bili največji v skupini bolnikov z aktivno boleznijo. Koncentracija bFGF je bila najmanjša pri bolnikih, ki niso potrebovali zdravljenja, ker je bila bolezen v obdobju remisije. Ugotovili smo dobro statistično povezanost med MMP-9 in VEGF. Koncentraciji VEGF in bFGF nista bili medsebojno povezani. Število trombocitov pa je bilo povezano z VEGF in MMP-6. Zaključki. Določanje dejavnikov angiogeneze je pomembno pri oceni aktivnosti bolezni. Koncentracije teh dejavnikov so večje pri bolnikih z aktivno razširjeno boleznijo.
Descriptors		MULTIPLE MYELOMA ANGIOGENESIS FACTOR FIBROBLAST GROWTH FACTOR, BASIC GELATINASES ENDOTHELIUM, VASCULAR